240 related articles for article (PubMed ID: 38627362)
1. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.
Leonard-Murali S; Bhaskarla C; Yadav GS; Maurya SK; Galiveti CR; Tobin JA; Kann RJ; Ashwat E; Murphy PS; Chakka AB; Soman V; Cantalupo PG; Zhuo X; Vyas G; Kozak DL; Kelly LM; Smith E; Chandran UR; Hsu YS; Kammula US
Nat Commun; 2024 Apr; 15(1):2863. PubMed ID: 38627362
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
[TBL] [Abstract][Full Text] [Related]
3. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
[TBL] [Abstract][Full Text] [Related]
4. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.
Rothermel LD; Sabesan AC; Stephens DJ; Chandran SS; Paria BC; Srivastava AK; Somerville R; Wunderlich JR; Lee CC; Xi L; Pham TH; Raffeld M; Jailwala P; Kasoji M; Kammula US
Clin Cancer Res; 2016 May; 22(9):2237-49. PubMed ID: 26712692
[TBL] [Abstract][Full Text] [Related]
5. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
[TBL] [Abstract][Full Text] [Related]
6. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives.
Kaštelan S; Antunica AG; Oresković LB; Pelčić G; Kasun E; Hat K
Curr Med Chem; 2020; 27(8):1350-1366. PubMed ID: 31272342
[TBL] [Abstract][Full Text] [Related]
8. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
9. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
Tavera RJ; Forget MA; Kim YU; Sakellariou-Thompson D; Creasy CA; Bhatta A; Fulbright OJ; Ramachandran R; Thorsen ST; Flores E; Wahl A; Gonzalez AM; Toth C; Wardell S; Mansaray R; Radvanyi LG; Gombos DS; Patel SP; Hwu P; Amaria RN; Bernatchez C; Haymaker C
J Immunother; 2018; 41(9):399-405. PubMed ID: 29757889
[TBL] [Abstract][Full Text] [Related]
10. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
11. Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.
Xia F; Yu Z; Deng A; Gao G
Exp Biol Med (Maywood); 2022 Feb; 247(3):246-262. PubMed ID: 34743576
[TBL] [Abstract][Full Text] [Related]
12. Identification of survival-related genes and a novel gene-based prognostic signature involving the tumor microenvironment of uveal melanoma.
Lei S; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107816. PubMed ID: 34162166
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of uveal melanoma.
Bosch JJ
Dev Ophthalmol; 2012; 49():137-149. PubMed ID: 22042018
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
15. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
Krishna Y; McCarthy C; Kalirai H; Coupland SE
Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
[TBL] [Abstract][Full Text] [Related]
17. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
[TBL] [Abstract][Full Text] [Related]
18. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
[No Abstract] [Full Text] [Related]
19. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
20. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
